Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  McLaughlin, Milena M ^a,b   Advincula, M R ^a   Malczynski, Michael ^b   Barajas, Grace ^c   Qi, Chao ^b,d   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Galleria mellonella; Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae; Mortality; Resistance; Virulence

Indexed keywords

CARBAPENEMASE; BACTERIAL PROTEIN; BETA LACTAMASE;

ADULT; AGED; ARTICLE; BACTERIAL VIRULENCE; BLOODSTREAM INFECTION; CONTROLLED STUDY; FEMALE; GALLERIA MELLONELLA; HUMAN; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR TYPING; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PILOT STUDY; PULSED FIELD GEL ELECTROPHORESIS; SCORING SYSTEM; SURVIVOR; ANIMAL; ANIMAL MODEL; BACTEREMIA; COMPARATIVE STUDY; ENZYMOLOGY; EPIDEMIOLOGY; HOST PATHOGEN INTERACTION; KLEBSIELLA; KLEBSIELLA INFECTIONS; LARVA; METABOLISM; MICROBIOLOGY; MOTH; PATHOGENICITY; RANDOMIZATION; RETROSPECTIVE STUDY; UNITED STATES; VIRULENCE;

ADULT; AGED; ANIMALS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CHICAGO; FEMALE; HOST-PATHOGEN INTERACTIONS; HUMANS; KLEBSIELLA; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LARVA; MALE; MIDDLE AGED; MODELS, ANIMAL; MOTHS; PILOT PROJECTS; RANDOM ALLOCATION; RETROSPECTIVE STUDIES; VIRULENCE;

EID: 84892643683     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-31     Document Type: Article

References (32)

1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009, 9:228-236. 10.1016/S1473-3099(09)70054-4, 19324295.
2. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
3. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, Schlaeffer F, Sherf M. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976. 10.1086/605922, 19712030.
4. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, Tsioka A, Roilides E, Sofianou D, Gritsi-Gerogianni N. Bloodstream infections caused by metallo-beta-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010, 31:1250-1256. 10.1086/657135, 20973725.
5. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-950. 10.1093/cid/cis588, 22752516.
6. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011, 17:1798-1803. 10.1111/j.1469-0691.2011.03514.x, 21595793.
7. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005, 26:346-351. 10.1086/502550, 15865269.
8. Kavanagh K, Reeves EP. Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens. FEMS Microbiol Rev 2004, 28:101-112. 10.1016/j.femsre.2003.09.002, 14975532.
9. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005, 73:3842-3850. 10.1128/IAI.73.7.3842-3850.2005, 1168598, 15972469.
10. Jander G, Rahme LG, Ausubel FM. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and Insects. J Bacteriol 2000, 182:3843-3845. 10.1128/JB.182.13.3843-3845.2000, 94559, 10851003.
11. Insua JL, Llobet E, Moranta D, Perez-Gutierrez C, Tomas A, Garmendia J, Bengoechea JA. Modeling Klebsiella pneumoniae Pathogenesis by Infection of the Wax Moth Galleria mellonella. Infect Immun 2013, 81:3552-3565. 10.1128/IAI.00391-13, 23836821.
12. Wand ME, McCowen JW, Nugent PG, Sutton JM. Use of the Galleria mellonella infection model to study the opportunistic pathogen Klebsiella pneumonia supports the presence of a multifaceted interaction with the host immune response. J Med Microbiol 2013, published online ahead of print.
13. Antunes LC, Imperi F, Carattoli A, Visca P. Deciphering the multifactorial nature of Acinetobacter baumannii pathogenicity. PLoS One 2011, 6:e22674. 10.1371/journal.pone.0022674, 3148234, 21829642.
14. Olsen RJ, Watkins ME, Cantu CC, Beres SB, Musser JM. Virulence of serotype M3 Group A Streptococcus strains in wax worms (Galleria mellonella larvae). Virulence 2011, 2:111-119. 10.4161/viru.2.2.14338, 3100763, 21258213.
15. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 2009, 53:2605-2609. 10.1128/AAC.01533-08, 2687231, 19332683.
16. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC, Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis 2009, 199:532-536. 10.1086/596511, 3750955, 19125671.
17. Senior NJ, Bagnall MC, Champion OL, Reynolds SE, La Ragione RM, Woodward MJ, Salguero FJ, Titball RW. Galleria mellonella as an infection model for Campylobacter jejuni virulence. J Med Microbiol 2011, 60:661-669. 10.1099/jmm.0.026658-0, 21233296.
18. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing 2010, Wayne, PA: Clinical and Laboratory Standards Institute, M100-S20, Clinical and Laboratory Standards Institute.
19. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233-2239. 228385, 7494007.
20. Mandrekar JN, Mandrekar SJ. Case-control study design: what, when, and why?. J Thorac Oncol 2008, 3:1371-1372. 10.1097/JTO.0b013e31818dd97b, 19057257.
21. Ury HK. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975, 31:643-649. 10.2307/2529548, 1100136.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
23. Thom KA, Shardell MD, Osih RB, Schweizer ML, Furuno JP, Perencevich EN, McGregor JC, Harris AD. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008, 29:1048-1053. 10.1086/591453, 2716043, 18817505.
24. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Scores 2012, Available at: http://ctep.cancer.gov. Accessed on 6 DEC, National Cancer Institute.
25. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-266. National Kidney Foundation.
26. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-212. 10.1186/cc2872, 522841, 15312219.
27. Wiskirchen DE, Nordmann P, Crandon J, Nicolau DP. Efficacy of Humanized Antibiotic Exposures against Enterobacteriaceae Producing the Oxa-48 Carbapenemase in a Murine Infection Model 2013, Denver, CO: 53rd Interscience Conference on Antimicrobials and Chemotherapy, Poster A-462.
28. Wiskirchen DE, Nordmann P, Crandon J, Nicolau DP. In-Vivo Efficacy of Humanized Regimens of Carbapenems and Comparators against NDM-1 Producing Enterobacteriaceae 2013, Denver, CO: 53rd Interscience Conference on Antimicrobials and Chemotherapy, Poster A-463.
29. Mukherjee K, Altincicek B, Hain T, Domann E, Vilcinskas A, Chakraborty T. Galleria mellonella as a model system for studying Listeria pathogenesis. Appl Environ Microbiol 2010, 76:310-317. 10.1128/AEM.01301-09, 2798647, 19897755.
30. Choi JY, Sifri CD, Goumnerov BC, Rahme LG, Ausubel FM, Calderwood SB. Identification of virulence genes in a pathogenic strain of Pseudomonas aeruginosa by representational difference analysis. J Bacteriol 2002, 184:952-961. 10.1128/jb.184.4.952-961.2002, 134824, 11807055.
31. Wand ME, Muller CM, Titball RW, Michell SL. Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol 2011, 11:11. 10.1186/1471-2180-11-11, 3025829, 21241461.
32. Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Threats in the United States, 2013 2013, Atlanta: CDC, Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf, Centers for Disease Control and Prevention (CDC).